IL27 Antibodies

Interleukin-27 subunit alpha (IL27)

Associates with EBI3 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, which may regulate T- helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells.

Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells.

Gene Information

Human
Gene Name:	IL27
Uniprot:	Q8NEV9
Entrez:	246778

Family

Belongs to:
IL-6 superfamily

Alternative Names

IL-27 p28 subunit; IL-27 subunit alpha; IL27; IL-27; IL27A; IL-27-A; IL27-A; IL27p28; IL30; interleukin 27; interleukin 30; interleukin-27 subunit alpha; MGC71873; p28IL-27A

Molecular Weight

Mass (kDA):
27.493 kDA

Genomic Context

Human
Location:	16p12.1-p11.2
Sequence:	16; NC_000016.10 (28499362..28526730, complement)

Tissue Specificity

Expressed in monocytes and in placenta.

Subcellular Localizations

Secreted. Does not seem to be secreted without coexpression of EBI3.

Diseases

• Inflammation
• Autoimmune Reaction
• Autoimmune Diseases
• Neoplasms
• Malignant Neoplasms
• Experimental Autoimmune Encephalomyelitis
• Encephalomyelitis
• Autoimmunity
• Carcinoma
• Crohn Disease
• Arthritis
• Rheumatoid Arthritis

• Infective Disorder
• Inflammatory Bowel Diseases
• Multiple Sclerosis
• Sclerosis
• Intestinal Diseases
• Colitis
• Ulcer

Interacting Proteins

• EBI3

Pathways

• Secretion
• Immune Response
• Pathogenesis
• Cytokine Production
• Cell Differentiation
• Cell Proliferation
• Cell Activation
• Inflammatory Response
• T Cell Activation
• Hypersensitivity
• T Cell Proliferation
• Cell Development
• Angiogenesis

• Cell Growth
• Chemokine Production
• Interferon-gamma Production
• Reverse Transcription
• Bone Resorption
• Mating
• Dna Methylation

PTMs

• Phosphorylation
• Cleavage
• Glycosylation

• Methylation
• Dephosphorylation
• Myristoylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/IL27

Best Uses Of The IL27 Marker

The IL27 marker has many benefits. It is well-known for its anti-inflammatory as well as pro-inflammatory properties. IL-27 is, in addition to its anti-inflammatory and anti-inflammatory properties, is an intriguing tool to manipulate the immune system. Learn more about its potential benefits and benefits. Listed below are some of the potential uses of the IL-27 marker.

IL-27, a heterodimeric cytokine is known as

The heterodimeric cytokine IL-27 is an IL-27 receptor-associated protein that functions through a number of different pathways. The WSX-1/TCCR complex is responsible for its biological effects. More research is required to determine how IL-27 influences macrophages in various tissues and activation states. In the meantime there is a growing amount of evidence that supports the role of IL-27 the regulation of T cell responses.

IL-27, a member the IL-12 family of proteins, is made by dendritic and macrophages that are activated cells. It affects NK and T cells by stimulating clonal expansion in naive CD4+T cells. Furthermore, it interacts with two distinct cell-surface receptors, IL27R as well as gp130.

The interface IL-27p28/EBI3 is a two-dimensional structure that can be classified into hydrophobic and polar areas. The hydrophobic zone contains an aromatic cluster of Phe97 and Trp97 within the EBI3 subunit while the polar region has residues that are involved in the formation of a salt bridge network. Arg219, Arg55 and IL-27p28 are located on the positively charged surface. The positively charged EBI3 surface has Glu124, Glu159, and Asp210.

IL-27p28 interacts with EBI3 to create a heterodimeric enzyme called cytokinase. This connection is broken down by an alteration in the subunit p28 of the protein, known as the W97A mutation. Mutations in both IL-27 and EBI3 identified the significance of the residues Phe97 and Asp210 in the formation of heterodimeric cytokines.

IL-27p28, in addition to p28 and IL-6 families of Cytokines, is a paralom for EBI3 (part of the IL-6 family). The cytokine complexes containing heterodimeric p28 subunits have the highest degree of similarity terms the gp130 binding position. P28 is an antagonist of the IL-6 signal, plays a critical role in the cytokines' function as a contextual molecule.

Most immune cells trigger IL-27 secretion. It is usually triggered by activation , such as LPS. Although the cytokine IL-27 is proinflammatory, it doesn't hinder the development of inflammatory disorders related to Th27. The secretion and function of IL-10 could be an anti-inflammatory property that could counteract IL-27-induced Th2 differentiation.

It has proand anti-inflammatory properties.

IL-27 is a heterodimeric cytokine that regulates immune responses both in the host and microbial environments. Early studies on IL27 revealed that it promoted Th2 responses. They also discovered molecular mechanisms. Further studies have shown that IL-27 reduces Th2 and Th2 responses which suggests that it has a dual function. In this study, we study the pleiotropic role of IL-27 and its potential application to cancer immunotherapy.

The IL-27 signaling pathway is critical in triggering immune responses during parasite infection. The IL-27 signaling pathway is also a crucial component of the immune response to parasite infection. It is linked to anti-inflammatory activities. Its biphasic function may facilitate therapeutic regulation. It is also crucial for the maintenance and development of an immune response within the host.

IL-27 has been shown to possess anti-inflammatory and anti-inflammatory properties. It also inhibits the production of cytokines that affect different types of immune cells. IL-27 deficiency causes arthritis by altering NK and CD4+ T cell proliferation and activation. The neutralization of IL27 helps to reduce arthritis in rats, suppresses T cell proliferation, and inhibits inflammatory cytokine release.

IL-27 hinders the differentiation of non-naive CD4+ T cells through interferon-gamma signaling. In addition, IL 27 binds to the WSX-1 transcription factor that is responsible for Th2 cell differentiation. Reduced transcription of GATA-3 inhibits the production of IL-4 by naive CD4+ T cells. T cells WSX-1-/CD4+, on the other hand produce more IL-5 during Th2 differentiation.

Inhibition by IL27-expressing CD8 T cells can reduce inflammation and lead to the development of Th27 cell. CD4 and CD8 CD8 T-cells inhibit production of IL-17. This can in turn reduce proinflammatory cytokine signals and cytokine cytokine.

WSX-1-/ mice have an increased susceptibility to intracellular pathogens and have a lesser ability to heal lesion following infection with Leishmania major. The mice lacking IL-27 exhibit impaired IFN-g production and reduced Th2 response, suggesting that IL-27 can suppress infection-induced responses. IL-27 could regulate Th2 responses' intensity and kinetics.

It's an anti-tumor agent.

Although it has been known for more than 10 years that IL27 has an important role as a tumor immune system, there has not been much progress in translating this information into a therapeutic strategy. This marker is made from recombinant Adeno-associated virus, (rAAV) which is a versatile gene delivery agent with low toxicity as well as high antitumor effects. AAV-IL27 was successfully delivered into tumor cells by recipients mice in this study. The tumor-bearing mice received the results of the protein, which slowed tumor growth. It also significantly improved the effectiveness of immunotherapy for cancer.

IL-27 induces CXCR3 expression on T cells and the CXCR3-induced CXCR3 expression is only visible on CD8+ T cells. CXCR3 inhibition inhibits tumor growth and kills cancer cells in dependent manner with nitric oxide. Additionally, IL-27 promotes the differentiation of T-bet-positive T cells in the bone marrow into antitumorigenic macrophages. In addition, it also helps to promote the development of myeloid progenitors.

To determine the antitumor effects of Boster Bio IL-27 CD8+ T cells were isolated from established J558 tumors. Five J558 cells in 100 ul were injected into BALB/c mice. When the tumors were 1 cm in length, the mice were killed. The tumors were crushed into single-cell suspensions. CD8 MicroBeads were utilized to isolate CD8+ TILs, and the cells were grown in RPMI 1640 with 10% fetal calf serum.

A separate study found that polymorphisms within the IL-27 gene were associated with a lower risk of bladder cancer. This suggested that polymorphisms in the IL-27 gene could have a role to play in bladder cancer. However, more studies are required to confirm the findings of this marker in patients suffering from cancer in the human body. This marker could be utilized in clinical settings as an aid in diagnosis.

This marker could be used in the near future to target PD-1 within tumor-bearing cells. These findings are positive and suggest that the IL-27 is an important new tool to alter the immune system. Its dual function in tumor immunity and the ability to pleiotropically function can aid in the development of innovative therapies. Clinical trials will need to be conducted before the results are discovered.

It could be a new tool to manipulate the immune system

Every disease is affected by the immune system, which is a collection of proteins, tissues and organs that are designed to defend against invaders. To assess the immune system doctors conduct a variety of tests, including checking the number of different types of T cells. The ability to run tests to determine the presence of antibodies can help in diagnosing serious illnesses, such as HIV or cancer. Modern medicine is based on immuno manipulative tools.